Vivos Therapeutics (VVOS) Profit After Tax (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Profit After Tax data on file, last reported at -$7.8 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 98.74% year-over-year to -$7.8 million in Q1 2026; TTM through Mar 2026 was -$25.1 million, a 122.69% decrease from a year earlier, with the FY2025 full-year figure at -$21.2 million, down 90.37% from the prior year.
• Profit After Tax for Q1 2026 stood at -$7.8 million, down from -$6.9 million in the prior quarter.
• Over the last five years, Profit After Tax for VVOS reached as high as -$1.7 million in Q1 2023 and fell as low as -$7.8 million in Q1 2026.
• Historically, Profit After Tax has averaged -$4.6 million across 5 years, with a median of -$5.0 million in 2025.
• Across the five-year window, Profit After Tax jumped 68.05% in 2023 and plunged 159.74% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$6.0 million in 2022, then grew by 28.33% to -$4.3 million in 2023, then surged by 34.05% to -$2.8 million in 2024, then plunged by 144.15% to -$6.9 million in 2025, then declined by 11.94% to -$7.8 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$7.8 million in Q1 2026, -$6.9 million in Q4 2025, and -$5.4 million in Q3 2025.